• Recognized by U.S. Key Opinion Leaders and BDMT Global consulting experts
• Comprehensive evaluation of medical AI innovation, market compatibility, and feasibility of entry
• Opportunity to expand the global network... pursuing a strategy to establish global references through adoption by North American medical institutions
Coreline Soft announced on the 7th that it has been selected as one of Fortune Korea's "Top 40 Emerging Korean Healthcare Innovations" (Fortune Korea's Top 40 'Emerging S. Korean Healthcare Innovations').
Fortune Korea, in collaboration with BDMT Global, a U.S.-based global business consulting firm, selected Key Opinion Leaders and experts based in the U.S. to review healthcare AI, digital health, and MedTech companies. The selection criteria included the feasibility of entering the U.S. healthcare market, innovation, and market fit, focusing on identifying innovative companies in these fields.
Coreline Soft has developed the technology to analyze multiple diseases such as lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery calcification (CAC) simultaneously using only a low-dose chest CT scan through its flagship product, "AVIEW LCS Plus." The company has established partnerships with leading U.S. medical institutions, including UMass Memorial Medical Center, a top 5 hospital in Massachusetts; Baylor College of Medicine (BCM) in Texas Medical Center (TMC); the largest medical imaging post-processing company in the U.S., 3DR Labs; and the Temple Lung Center. Additionally, Coreline Soft is accelerating its expansion into the North American market by jointly promoting workshops integrating Microsoft’s PowerScribe, a reporting system with a 70% market share in the U.S., enhancing the system's scalability.
The company is also actively participating in lung cancer screening projects across Europe, supplying products to key projects in countries like Germany, Italy, and the UK. It has secured a leading position in healthcare AI by providing solutions to Oxford University Hospital, one of the world’s top university hospitals, and six out of the top ten German hospitals. The company explained, “This recognition reflects not only our technological capabilities but also the broader assessment of adoption and results achieved in major hospitals, which supports the high-growth potential within North America.”
With this selection, Coreline Soft will leverage BDMT Global’s extensive international network, gaining priority registration for major healthcare conferences held in Boston, U.S., as well as networking opportunities with Key Opinion Leaders (KOLs). Kim Jin-guk, CEO of Coreline Soft, stated, “We plan to expand our hospital customer base in the U.S. and further extend our global industrialization model.”
Meanwhile, Coreline Soft has obtained certifications such as FDA, CE, HIPAA, GDPR, and was the first Korean medical AI company to achieve the ISO/IEC 42001 certification, an international standard for AI management systems. Last month, the company also secured a U.S. patent for its "dual AI structure" technology, which enhances AI reliability.
